Schilke Tobin

CIK 00016789843 companiesSAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001678984

Recent Transactions

50 trades

Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2025-03-10+52,000→ 52,000 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2025-03-10+80,000→ 80,000 total
Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−20,883→ 0 total
Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−103,555→ 0 total
Award
Revance Therapeutics, Inc.
Common Stock
2025-02-06+20,883→ 20,883 total
Disposition from Tender
Revance Therapeutics, Inc.
Common Stock
2025-02-04$3.65/sh−97,999→ 103,555 total
Award
Revance Therapeutics, Inc.
Common Stock
2025-02-03+6,888→ 201,554 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-12-31$2.18/sh+1,000→ 194,666 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-06-30$2.18/sh+1,000→ 193,666 total
Sale
Revance Therapeutics, Inc.
Common Stock
2024-03-18$5.04/sh−9,361→ 192,666 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2024-03-15$5.30/sh−3,822→ 202,027 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-02-29+17,447→ 205,849 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-01-31+96,667→ 188,402 total
Award
Revance Therapeutics, Inc.
Performance Stock Units
2024-01-31+145,001→ 145,001 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-12-31$7.47/sh+434→ 91,735 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-08-11+22,620→ 102,516 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-08-11$18.91/sh−11,215→ 91,301 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-07-03$25.04/sh−1,701→ 79,896 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-06-30$15.61/sh+769→ 81,597 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-06-02$31.00/sh−500→ 80,828 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-06-01$30.57/sh−2,701→ 81,328 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-05-15$34.55/sh−21,401→ 84,029 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-05-01$31.70/sh−3,201→ 63,081 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-04-03$32.15/sh−3,201→ 66,282 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-03-15$30.65/sh−3,739→ 69,483 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-03-09$31.59/sh−18,517→ 73,222 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-03-01$33.50/sh−3,201→ 49,390 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-02-15$33.21/sh−2,085→ 52,591 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-02-01$34.60/sh−3,201→ 54,676 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2023-01-31+50,435→ 50,435 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-09$28.00/sh−1,000→ 59,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-09$30.00/sh−1,000→ 58,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-09$25.00/sh−1,701→ 60,877 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+645→ 62,578 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-12-15$21.50/sh−1,557→ 61,933 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-09-22+42,349→ 91,739 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-06-30$11.75/sh+965→ 63,490 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-03-15$15.79/sh−2,607→ 62,525 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-02-15$13.35/sh−2,241→ 65,815 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-02-15$13.35/sh−683→ 65,132 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2022-02-02+68,093→ 68,093 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-02-02+42,349→ 105,430 total
Other
Revance Therapeutics, Inc.
Common Stock
2021-12-31$13.87/sh+404→ 68,056 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-12-15$15.92/sh−1,556→ 67,652 total
Other
Revance Therapeutics, Inc.
Common Stock
2021-06-30$24.09/sh+446→ 69,208 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-02-15$28.97/sh−684→ 70,735 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-02-15$28.97/sh−1,973→ 68,762 total
Award
Revance Therapeutics, Inc.
Common Stock
2021-02-02+22,620→ 71,419 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2021-02-02+40,925→ 40,925 total

Companies

Recent Filings

Address

C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD

SAN DIEGO, CA, 92121

View on SEC.gov